AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Novel Coronavirus Treatment

864.254

+8.7191.02%

Number of Gainers:7

Number of Losers:12

Number of Flat:13

PE:- -

High:865.461

Open:856.807

Low:854.414

Close:855.535

Volume:14.23M

Turnover:218.45M

Market Cap:217.87B

Float Cap:173.08B

Loading ...

Is CSL’s US$3 Billion US Manufacturing Push Altering The Investment Case For CSL (ASX:CSL)?

Simply Wall St.

How I'd build a world-class ASX passive income portfolio

These 3 ASX ETFs can help protect your portfolio in 2026

ResMed (RMD) Is Down 5.1% After Market Value Slides Despite Solid Fundamentals Has The Bull Case Changed?

Simply Wall St.

2 battered ASX growth shares that could double in value or more

Down 20% in 2026, is now the time to buy CSL shares?

CSL and these ASX 200 stocks just hit 52-week lows: Should you buy the dip?

Ansell's Margins Could Be Hit by Oil Disruptions -- Market Talk

3 ways to get from $100,000 to $1 million in retirement savings

How are Australia's biggest blue-chip stocks performing in 2026?

How to invest when the ASX refuses to calm down

Should I invest $5,000 in Coles shares now?

Is American Tower (AMT) Pricing Reflecting DCF And P/E Signals After REIT Rate Jitters

Simply Wall St.

Mesoblast Director Philip James Facchina Files Initial Beneficial Ownership Statement

Mesoblast director Jane Catherine Bell files Form 3 initial beneficial ownership statement

Mesoblast names CFO James Michael O’Brien in initial beneficial ownership filing

Mesoblast names Chief Medical Officer and Director Eric Allen Rose in initial beneficial ownership filing

CSL Finance Gets Board Nod to Raise Up To INR1.50 Billion Through Debenture Issue

MT Newswires Live

3 reasons to buy CSL shares today

New Zealand Supermarkets Receive Notice From Grocery Commissioner

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7501/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"Novel Coronavirus Treatment","latestPrice":864.25433,"timestamp":1774501199601,"preClose":855.53516,"halted":0,"volume":14229036,"delay":0,"changeRate":0.010191,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":8.719177,"latestTime":"03-26 16:00:00 AEDT","open":856.80743,"high":865.46063,"low":854.4144,"amount":218447083,"amplitude":0.012911,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774566000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774479600000,1774501200000]],"turnoverRate":0.000991,"increases":9,"decrements":11,"flats":12,"marketCap":217869983444.5,"floatMarketCap":173082365288.08594},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":865.46063,"amplitude":0.012911,"preClose":855.53516,"low":854.4144,"latestPrice":864.25433,"volume":14229036,"delay":0,"open":856.80743,"prevYearClose":900.1661,"prevWeekClose":840.804,"prevMonthClose":875.89,"prevQuarterClose":900.166,"fiveDayClose":836.778,"twentyDayClose":886.189,"sixtyDayClose":900.477,"secType":"PLATE","market":"AU","turnoverRate":0.000991,"marketCap":217869983444.5,"floatMarketCap":173082365288.08594,"timestamp":1774501199601,"nameCN":"Novel Coronavirus Treatment"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":7,"down":12,"flat":13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620209857","title":"Is CSL’s US$3 Billion US Manufacturing Push Altering The Investment Case For CSL (ASX:CSL)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620209857","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620209857?lang=en_us&edition=fundamental","pubTime":"2026-03-20 09:13","pubTimestamp":1773969194,"startTime":"0","endTime":"0","summary":"Earlier this month, CSL broke ground on a major expansion of its Kankakee, Illinois manufacturing facility, aiming to boost plasma-derived therapy and albumin output using its patented Horizon 2 process while adding at least 300 new pharmaceutical roles and about 800 construction jobs.\nThis multiyear U.S. build-out, part of more than US$3.00 billion invested in American operations since 2018, signals CSL’s intention to deepen its U.S. manufacturing base and improve plasma efficiency to...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csls-us3-billion-us-manufacturing-push-altering-the-inves","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csls-us3-billion-us-manufacturing-push-altering-the-inves","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4551","BK4588","AIYY","SG9999004303.SGD","BK4585","BK7067","BK4086","LU1169590202.USD","BK7508","BK4543","CSL","LU0728928796.USD","BK4023","BK7511","BK4528","BK7501","LU1169589451.USD","AI","BK4587","CSL.AU","SGXZ23171101.USD"],"gpt_icon":0},{"id":"2620120818","title":"How I'd build a world-class ASX passive income portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2620120818","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620120818?lang=en_us&edition=fundamental","pubTime":"2026-03-20 08:53","pubTimestamp":1773967989,"startTime":"0","endTime":"0","summary":"Building a passive income portfolio isn't about chasing the highest dividend yield.If anything, that's one of the easiest ways to get into trouble.What I'd focus on instead is building something that can grow, adapt, and keep paying me for decades. The goal is reliability first, income second, and growth quietly working in the background.For me, that includes names like Commonwealth Bank of Australia , Woolworths Group Ltd , and Wesfarmers Ltd .Transurban Group  is a good example, with toll roads that benefit from long-term concessions and population growth. Telstra Group Ltd  also fits here, with recurring revenue from its telecommunications network.That could include businesses like REA Group Ltd  or even TechnologyOne Ltd , where earnings growth has historically supported rising payouts.A fund like Vanguard Australian Shares High Yield ETF  can provide exposure to a broad basket of dividend-paying companies, helping to reduce reliance on any single stock.For me, ETFs are less about ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/how-id-build-a-world-class-asx-passive-income-portfolio/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/20/how-id-build-a-world-class-asx-passive-income-portfolio/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7002","WES.AU","BK7016","VDHG.AU","BK7153","BK7507","BK7090","BK7040","TNE.AU","TLS.AU","TCL.AU","BK7095","WOW.AU","REA.AU","BK7511","BK7042","BHP.AU","BK7041","BK7503","VHY.AU","BK7135","BK7501","CBA.AU"],"gpt_icon":0},{"id":"2620271903","title":"These 3 ASX ETFs can help protect your portfolio in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620271903","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620271903?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:00","pubTimestamp":1773954000,"startTime":"0","endTime":"0","summary":"ASX investors are a patriotic lot. We tend to prioritise buying shares on our local stock market. Stocks like Commonwealth Bank of Australia (ASX: CBA), Telstra Group Ltd (ASX: TLS), Woolworths Group ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/these-3-asx-etfs-can-help-protect-your-portfolio-in-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/20/these-3-asx-etfs-can-help-protect-your-portfolio-in-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7135","XKO.AU","WBC.AU","BK7042","IVE.AU","CBA.AU","XJO.AU","VGE.AU","WOW.AU","BK7511","BK7501","BK7040","VEU.AU","XAO.AU","TLS.AU"],"gpt_icon":0},{"id":"2620275561","title":"ResMed (RMD) Is Down 5.1% After Market Value Slides Despite Solid Fundamentals Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620275561","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620275561?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:09","pubTimestamp":1773947367,"startTime":"0","endTime":"0","summary":"In the past week, ResMed’s share price weakness has erased about US$3.30 billion from its market value, leaving the company at roughly US$34.00 billion despite reports that its operating performance and financial condition remain solid.\nThis disconnect between market sentiment and underlying business health raises questions about whether recent trading reflects short-term emotion rather than changes in ResMed’s long-term outlook.\nAgainst this backdrop of recent market value erosion despite...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-is-down-51-after-market-value-slides-despite-soli","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-is-down-51-after-market-value-slides-despite-soli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AI","BK4504","BK4548","LU0170899867.USD","BK4023","BK4528","LU2177674079.SGD","BK4551","LU2008162690.USD","BK7501","BK4587","BK4567","RMD.AU","BK4588","AIYY","BK7007","IE00B5TLWC47.USD","BK4543","RMD","BK4082","BK4585"],"gpt_icon":0},{"id":"2620275862","title":"2 battered ASX growth shares that could double in value or more","url":"https://stock-news.laohu8.com/highlight/detail?id=2620275862","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620275862?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:00","pubTimestamp":1773946800,"startTime":"0","endTime":"0","summary":"It's been a bruising start to 2026 for many ASX growth shares, with some among the biggest victims of this year's market onslaught.Two names that stand out are Mesoblast Ltd  and Zip Co Ltd . At the time of writing, Mesoblast shares are down 23% year to date to $2.08, while Zip has plunged 52% to $1.48.By comparison theS&P/ASX 200 Indexhas shed 2.5% of its value so far this year.But after such steep declines for both ASX growth shares, could this be a classic buy the dip opportunity?This ASX growth share is no stranger to volatility, with its share price often swinging sharply on clinical updates and regulatory news.Even so, analysts remain optimistic on the ASX growth share, with an average 12-month price target of $4.23. This implies upside of around 104% from current levels.Rising interest rates, regulatory scrutiny, and concerns about consumer spending have all contributed to the sharp decline of the ASX growth share.After significant share price declines, they may be worth a close","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/2-battered-asx-growth-shares-that-could-double-in-value-or-more/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/20/2-battered-asx-growth-shares-that-could-double-in-value-or-more/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7093","XJO.AU","BK7508","BK7501","MSB.AU","ZIP.AU"],"gpt_icon":0},{"id":"2620699215","title":"Down 20% in 2026, is now the time to buy CSL shares?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620699215","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620699215?lang=en_us&edition=fundamental","pubTime":"2026-03-19 12:54","pubTimestamp":1773896095,"startTime":"0","endTime":"0","summary":"TheCSL Ltd share price is heading south today, with the biotech giant continuing a difficult run.At the time of writing, the CSL share price is down 1.91% to $135.37, after falling as low as $133.35 earlier in the session. That marks a new multi-year low, with the stock last trading at these levels back in September 2017.The decline means CSL shares are now down around 22% in 2026. This raises the question of whether this is a buying opportunity or if the share price has further to fall.Over the past year, the stock has consistently made lower highs and lower lows. The latest move to multi-year lows reinforces that trend, with no clear signs of a reversal.At the same time, the share price is trading well below key moving averages, which tell us sellers are still in control.At the same time, broader market conditions have not helped. Healthcare stocks have lagged in 2026, while investors have shifted towards sectors such as resources and energy.That means the next move will likely depen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/down-20-in-2026-is-now-the-time-to-buy-csl-shares/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/down-20-in-2026-is-now-the-time-to-buy-csl-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SG9999004303.SGD","LU1169590202.USD","RSI","CSL.AU","BK7501","BK7067","BK7511","LU1169589451.USD","BK4086","BK4150","LU0728928796.USD","SGXZ23171101.USD","CSL","BK7508"],"gpt_icon":0},{"id":"2620290420","title":"CSL and these ASX 200 stocks just hit 52-week lows: Should you buy the dip?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620290420","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620290420?lang=en_us&edition=fundamental","pubTime":"2026-03-19 11:03","pubTimestamp":1773889412,"startTime":"0","endTime":"0","summary":"It's been a tough session for the market. After a weak lead from Wall Street overnight, the ASX 200 is down around 1.55% at the time of writing on Thursday. That takes losses for March to roughly 7.5%, which is a meaningful pullback in such a short period.Whenever markets fall like this, quality stocks tend to get dragged down with everything else.That's exactly what we're seeing right now, with several well-known ASX 200 stocks hitting 52-week lows. The key question is: is this an opportunity for investors?CSL has been under pressure for a while now, and this latest selloff has pushed it to fresh lows.Sentiment has clearly turned cautious, but I don't think the long-term story has changed in any meaningful way.This is still one of Australia's highest-quality healthcare companies, with global scale, strong margins, and a long track record of innovation.Short-term earnings noise and investor concerns can move the share price around, but over time, businesses like CSL tend to reflect the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/csl-and-these-asx-200-stocks-just-hit-52-week-lows-should-you-buy-the-dip/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/csl-and-these-asx-200-stocks-just-hit-52-week-lows-should-you-buy-the-dip/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","BK4086","BK7067","ALL.AU","BK7508","COH.AU","BK7007","CSL","LU1169590202.USD","LU1169589451.USD","CSL.AU","BK7511","SG9999004303.SGD","BK7063","LU0728928796.USD","SGXZ23171101.USD","AMC.AU","BK7078"],"gpt_icon":0},{"id":"2620299967","title":"Ansell's Margins Could Be Hit by Oil Disruptions -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2620299967","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620299967?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:16","pubTimestamp":1773879360,"startTime":"0","endTime":"0","summary":"0016 GMT - Ansell's FY 2027 margins could be hit by rising raw material costs stemming from the disruption of global oil supplies, Citi analyst Laura Sutcliffe warns. She acknowledges that the personal-protective equipment maker has shown recently it can successfully pass costs onto its customers but still thinks that input costs could have an impact. She tells clients in a note that the consensus forecast is for Ansell's FY 2027 Ebit margin to expand by 20 bps over FY 2026. Sutcliffe observes that one of Ansell's rivals has flagged nitrile latex availability issues. Nitrile latex is a key glove ingredient and represents 20%-25% of Ansell's raw material costs, she adds. Ansell has a neutral rating and A$35.00 target price on Ansell's stock, which is down 3.9% at A$28.59. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANN.AU","BK7126","BK7501"],"gpt_icon":0},{"id":"2620829538","title":"3 ways to get from $100,000 to $1 million in retirement savings","url":"https://stock-news.laohu8.com/highlight/detail?id=2620829538","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620829538?lang=en_us&edition=fundamental","pubTime":"2026-03-19 06:39","pubTimestamp":1773873567,"startTime":"0","endTime":"0","summary":"Hitting your first $100,000 in retirement savings is a big milestone.  But the next goal, reaching $1 million, can feel a lot further away. The good news is that once you've built that initial base, t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/3-ways-to-get-from-100000-to-1-million-in-retirement-savings/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/3-ways-to-get-from-100000-to-1-million-in-retirement-savings/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CBA.AU","MQG.AU","RMD.AU","BK7501","BK7511","BK7007","BK7046","IVV.AU","BK7135"],"gpt_icon":0},{"id":"2620459260","title":"How are Australia's biggest blue-chip stocks performing in 2026?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620459260","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620459260?lang=en_us&edition=fundamental","pubTime":"2026-03-19 05:14","pubTimestamp":1773868474,"startTime":"0","endTime":"0","summary":"Despite the S&P/ASX 200 Index (ASX: XJO) being Australia's benchmark index, it is highly concentrated towards a few blue-chip stocks. In fact, the ASX 200 is one of the most concentrated developed-mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/how-are-australias-biggest-blue-chip-stocks-performing-in-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/how-are-australias-biggest-blue-chip-stocks-performing-in-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7135","BK4535","BK7153","BK7511","BK7501","BK4588","BHP.AU","WES.AU","BK7507","BK7095","BK7508","BK7041","CBA.AU","CSL.AU","BK7067","BK4585"],"gpt_icon":0},{"id":"2620126236","title":"How to invest when the ASX refuses to calm down","url":"https://stock-news.laohu8.com/highlight/detail?id=2620126236","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620126236?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:12","pubTimestamp":1773864760,"startTime":"0","endTime":"0","summary":"The Australian share market has been anything but steady in 2026. Current futures contracts are pointing to a 1.6% decline on Thursday following a weak lead from Wall Street, continuing a run of sharp moves in both directions over recent weeks. This volatility has been driven by a mix of factors. Investors are weighing the impact of artificial intelligence, including concerns about disruption and whether massive infrastructure spending is getting ahead of demand. At the same time, surging oil prices linked to conflict in the Middle East and higher interest rates are adding further uncertainty. So, how should investors respond when markets refuse to settle?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/how-to-invest-when-the-asx-refuses-to-calm-down/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/how-to-invest-when-the-asx-refuses-to-calm-down/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7510","BK7090","BK7511","BK7042","BK7040","RMD.AU","WOW.AU","BK7099","BK7155","BK7007","BK7501","GMG.AU","TLS.AU","TCL.AU"],"gpt_icon":0},{"id":"2620501972","title":"Should I invest $5,000 in Coles shares now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620501972","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620501972?lang=en_us&edition=fundamental","pubTime":"2026-03-18 23:30","pubTimestamp":1773847800,"startTime":"0","endTime":"0","summary":"I'd be comfortable investing $5,000 in Coles shares today. This is because I think it offers a combination of a more attractive entry point, reliable, fully-franked income, a defensive business model, and ongoing operational improvements.  Overall, it's the kind of stock I'd be comfortable owning through different market conditions. Foolish Takeaway Coles shares aren't likely to double overnight. That's not the point. At around 13.5% below their recent high, offering steady dividends and backed by a resilient business, I think they're a solid option for a $5,000 investment today.  For me, it's a reminder that sometimes the best opportunities aren't the most exciting ones.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/should-i-invest-5000-in-coles-shares-now/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/should-i-invest-5000-in-coles-shares-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","COL.AU","BK7040","BK7082"],"gpt_icon":0},{"id":"2620257063","title":"Is American Tower (AMT) Pricing Reflecting DCF And P/E Signals After REIT Rate Jitters","url":"https://stock-news.laohu8.com/highlight/detail?id=2620257063","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620257063?lang=en_us&edition=fundamental","pubTime":"2026-03-18 22:11","pubTimestamp":1773843079,"startTime":"0","endTime":"0","summary":"If you are trying to work out whether American Tower is attractively priced or not, the recent share performance gives you a useful starting point but not the full story.\nThe stock last closed at US$185.07, with returns of a 0.6% decline over 7 days, a 3.7% decline over 30 days, a 5.9% gain year to date, and a 10.8% decline over 1 year.\nRecent headlines have focused on American Tower as a key player in listed real estate focused on telecom infrastructure, alongside ongoing attention on...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/24766-main-header/1756252641913","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/24766-main-header/1756252641913"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-amt/american-tower/news/is-american-tower-amt-pricing-reflecting-dcf-and-pe-signals","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-amt/american-tower/news/is-american-tower-amt-pricing-reflecting-dcf-and-pe-signals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4554","BK4581","BK4588","BK6142","BK4219","AMT","DCF","BK4534","BK4585","BK7501","CFA.SI","REIT","8C8U.SI","BK4084","BK7007","AMT.AU"],"gpt_icon":0},{"id":"2620251603","title":"Mesoblast Director Philip James Facchina Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251603","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251603?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:41","pubTimestamp":1773841317,"startTime":"0","endTime":"0","summary":"Philip James Facchina, a director of Mesoblast, filed an initial statement of beneficial ownership. The filing reported 123,220 ordinary shares held indirectly through HNP. It also listed director-held options covering 66,667 ordinary shares at an exercise price of AUD 2.26. Additional director-held options covered 96,811 ordinary shares at an exercise price of AUD 0.36. The filing reported indirect warrants through HNP for 68,306 ordinary shares at an exercise price of AUD 2.86.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5ctL40:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","MSB.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2620251643","title":"Mesoblast director Jane Catherine Bell files Form 3 initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251643","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251643?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:40","pubTimestamp":1773841238,"startTime":"0","endTime":"0","summary":"Mesoblast director Jane Catherine Bell filed an initial statement of beneficial ownership. The filing reported 622,492 ordinary shares held indirectly via a self-managed superannuation fund. It also reported stock options to buy ordinary shares totaling 719,037 shares. The options carried exercise prices of AUD 0.36, AUD 0.83, and AUD 0.97.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5m0b48:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MSB.AU","BK7501","BK7508"],"gpt_icon":0},{"id":"2620251342","title":"Mesoblast names CFO James Michael O’Brien in initial beneficial ownership filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251342","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251342?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:35","pubTimestamp":1773840949,"startTime":"0","endTime":"0","summary":"Mesoblast reported an initial statement of beneficial ownership by James Michael O'Brien, its Chief Financial Officer. The filing stated that O'Brien beneficially owned no Mesoblast securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL64jXpp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2620251348","title":"Mesoblast names Chief Medical Officer and Director Eric Allen Rose in initial beneficial ownership filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251348","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251348?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:35","pubTimestamp":1773840903,"startTime":"0","endTime":"0","summary":"Mesoblast reported that Eric Allen Rose filed an initial statement of beneficial ownership as Chief Medical Officer and director. Rose reported direct ownership of 6,749,274 ordinary shares. He also reported options to buy 6,416,519 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3HwLLB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2620234200","title":"CSL Finance Gets Board Nod to Raise Up To INR1.50 Billion Through Debenture Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2620234200","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620234200?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:24","pubTimestamp":1773829457,"startTime":"0","endTime":"0","summary":"CSL Finance  has received board approval to raise up to 1.50 billion Indian rupees through the issue of non-convertible debentures on a private placement basis, according to a Wednesday filing to the Indian stock exchanges.The company plans to issue various types of debentures in one or more tranches, details of which will be decided by the board.The debentures are proposed to be listed on the BSE.The company's shares are up nearly 1% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1169590202.USD","BK4086","BK7508","LU1169589451.USD","LU0728928796.USD","BK7067","SG9999004303.SGD","CSL","SGXZ23171101.USD","BK7501","CSL.AU","BK7511"],"gpt_icon":0},{"id":"2620301286","title":"3 reasons to buy CSL shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2620301286","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620301286?lang=en_us&edition=fundamental","pubTime":"2026-03-18 11:57","pubTimestamp":1773806278,"startTime":"0","endTime":"0","summary":"CSL Ltd (ASX: CSL) shares are down 1.4% in Wednesday afternoon trade. At the time of writing, the beaten-down biotech stock is trading at $139.13 per share.  Today's decline means the shares are now d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/3-reasons-to-buy-csl-shares-today-3/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/3-reasons-to-buy-csl-shares-today-3/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7501","SGXZ23171101.USD","BK7508","CSL","LU0728928796.USD","LU1169589451.USD","LU1169590202.USD","BK7511","BK4086","SG9999004303.SGD","CSL.AU"],"gpt_icon":0},{"id":"2620863662","title":"New Zealand Supermarkets Receive Notice From Grocery Commissioner","url":"https://stock-news.laohu8.com/highlight/detail?id=2620863662","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620863662?lang=en_us&edition=fundamental","pubTime":"2026-03-18 11:53","pubTimestamp":1773805988,"startTime":"0","endTime":"0","summary":"New Zealand Grocery Commissioner Pierre Heerden said he has put supermarkets on notice that they should not seek additional margin from rising costs linked to the Middle East conflict, and that any price increases should be reversed as soon as possible, according to a Wednesday RNZ report.Heerden said supermarkets had indicated that the additional costs had not yet been passed on to consumers, though he cautioned that this would depend on how long the conflict continued, the report added.Gemma Rasmussen, Consumer NZ's head of advocacy, said that New Zealand should consider an excessive pricing regime similar to one in Australia, which would cap supermarket markups and impose penalties of up to AU$10 million for breaches.Shares of Woolworths Group , which has operations in New Zealand, were marginally higher in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["T10G.NZ","BK7501","BK7040","NZ20C.NZ","BK7511","NZ50G.NZ","WOW.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":115,"code":"91000000","status":"200"}]}}